readthroughSign in
Nov 17, 2026Clinical readout

MAIA reports 88% disease control rate in expanded Phase 2 THIO-101 lung cancer trial

Combined data from Parts A, B and C of the ateganosine study in third-line NSCLC show consistent efficacy as the patient pool grows, MAIA said.

MAIA Biotechnology announced updated interim efficacy data on November 17, 2026 from Part C of its Phase 2 THIO-101 expansion trial testing ateganosine, a telomere-targeting agent, as a third-line treatment for advanced non-small cell lung cancer. Part C is enrolling additional patients to confirm the efficacy already observed in Parts A and B of the study.1

The trial enrolls advanced NSCLC patients who did not respond to or progressed after prior immune checkpoint inhibitor therapy and chemotherapy, treating them with ateganosine 180mg followed by cemiplimab (Libtayo) in 21-day cycles.1 Across Parts A, B and C as of October 1, 2026, the disease control rate for third-line NSCLC patients resistant to chemotherapy and immunotherapy was 88%, based on 38 of 43 evaluable patients who had at least one tumor scan after starting treatment.1 The company said this compares with a reported 25%–35% disease control rate for standard third-line chemotherapy regimens.1

MAIA has completed enrollment in Part C of the Phase 2 expansion, which included sites in Hungary, Poland, Turkey, Georgia, Romania, Taiwan and the United States.1 A separate pivotal Phase 3 trial, THIO-104, targeting the same third-line population as THIO-101 Part C, is advancing toward regulatory milestones including a planned 2027 interim survival analysis.1

According to the release's title, the company cited the data as supporting further development under the FDA's Fast Track designation, and said additional data from Part C could support an accelerated approval filing.

Ateganosine is MAIA's lead program, described as a potential first-in-class cancer telomere-targeting agent in development for NSCLC patients with telomerase-positive cancer cells.1 More information on the trial is available on ClinicalTrials.gov under identifier NCT05208944.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.